SGAM
ALLO icon

Smith Group Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Smith Group Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-60
Closed -$2K – 369
2021
Q2 		$2K Hold
60
– – ﹤0.01% 356
2021
Q1 		$2K Sell
60
-1,900
-97% -$64.1K ﹤0.01% 323
2020
Q4 		$49K Sell
1,960
-10
-0.5% -$326 ﹤0.01% 219
2020
Q3 		$74K Buy
+1,970
New +$74.3K ﹤0.01% 206

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Smith Group Asset Management's ALLO Position: Q3 2021 in Review

Smith Group Asset Management sold out of Allogene Therapeutics (ALLO) in Q3 2021, closing a stake of 60 shares — an estimated $2K sold.

Smith Group Asset Management first reported a position in ALLO in Q3 2020 and held it in 4 quarters. The position peaked at $74K in Q3 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

  • Smith Group Asset Management reported no remaining Allogene Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Smith Group Asset Management sold 60 Allogene Therapeutics shares in Q3 2021, an estimated $2K.
  • Smith Group Asset Management first reported a position in Allogene Therapeutics in Q3 2020 and held it in 4 quarters.
  • Smith Group Asset Management's Allogene Therapeutics position peaked at $74K in Q3 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.